Welcome

Sign out Have a question? We're here to help

Sign out

Atyr Pharma Inc (LIFE)

$2.90 0.34 (13.28%)

17:18 EDT LIFE Stock Quote Delayed 20 Minutes

Volume:

Previous Close $2.90

Market Cap 86.50M

PE Ratio -1.74

EPS -1.67

Volume (Avg. Vol.) 140,000

Day's Range 2.40 - 2.97

52-Week Range 0.31 - 7.62

Dividend & Yield N/A (N/A)

LIFE Stock Predictions, Articles, and Atyr Pharma Inc News

From InvestorPlace
From the Web

5 Stocks to Add to Your Portfolio on New Analyst Coverage

By Zacks Investment Research Oct 10, 2017

Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

Best & Worst Performing Small Cap Stocks for April 3, 2020

From StockNews.com Apr 3, 2020

ECOR – ECOR leads the way today as the best performing small cap stock, closing up 37.33%.

The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance

From Benzinga Mar 27, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday. Down In The...

Atyr Pharma (LIFE) Reports Q4 Loss, Beats Revenue Estimates (Revised)

From Zacks Investment Research Mar 27, 2020

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Oppenheimer Maintains a Buy Rating on aTyr Pharma (LIFE)

From Analyst Ratings Mar 27, 2020

Oppenheimer analyst Hartaj Singh maintained a Buy rating on aTyr Pharma (LIFE – Research Report) today and set a price target of $8.00. The company’s shares closed last Monday at $3.08, close to its 52-week low of $2.13. According to TipRanks.com, Singh is a 3-star analyst with an average return of 0.2% and a 39.6%

Atyr Pharma (LIFE) Reports Q4 Loss, Lags Revenue Estimates

From Zacks Investment Research Mar 26, 2020

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

From Benzinga Mar 26, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) Ra Pharmaceuticals Inc (...

Navellier Ratings

Total Grade

Hold

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Atyr Pharma Inc (LIFE)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Atyr Pharma Inc (LIFE)

LIFE Stock Predictions, Articles, and Atyr Pharma Inc News

5 Stocks to Add to Your Portfolio on New Analyst Coverage

Best & Worst Performing Small Cap Stocks for April 3, 2020

The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance

Atyr Pharma (LIFE) Reports Q4 Loss, Beats Revenue Estimates (Revised)

Oppenheimer Maintains a Buy Rating on aTyr Pharma (LIFE)

Atyr Pharma (LIFE) Reports Q4 Loss, Lags Revenue Estimates

The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

Navellier Ratings

Total Grade

Subscriber Sign in